Literature DB >> 23551736

Reply to Visit-to-visit blood pressure variation: time to reanalyze all the data from the TROPHY study.

Stevo Julius, Niko Kaciroti, Suzanne Oparil.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23551736      PMCID： PMC8033912          DOI： 10.1111/jch.12069

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  7 in total

1.  A Bayesian model for time-to-event data with informative censoring.

Authors:  Niko A Kaciroti; Trivellore E Raghunathan; Jeremy M G Taylor; Stevo Julius
Journal:  Biostatistics       Date:  2012-01-04       Impact factor: 5.899

2.  A Bayesian sensitivity model for intention-to-treat analysis on binary outcomes with dropouts.

Authors:  Niko A Kaciroti; M Anthony Schork; Trivellore Raghunathan; Stevo Julius
Journal:  Stat Med       Date:  2009-02-15       Impact factor: 2.373

3.  TROPHY study: Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension.

Authors:  Stevo Julius; Niko Kaciroti; Brent M Egan; Shawna Nesbitt; Eric L Michelson
Journal:  J Am Soc Hypertens       Date:  2008 Jan-Feb

4.  Feasibility of treating prehypertension with an angiotensin-receptor blocker.

Authors:  Stevo Julius; Shawna D Nesbitt; Brent M Egan; Michael A Weber; Eric L Michelson; Niko Kaciroti; Henry R Black; Richard H Grimm; Franz H Messerli; Suzanne Oparil; M Anthony Schork
Journal:  N Engl J Med       Date:  2006-03-14       Impact factor: 91.245

5.  The short treatment with the angiotensin receptor blocker candesartan surveyed by telemedicine (STAR CAST) study: rationale and study design.

Authors:  Hiroyuki Sasamura; Hideaki Nakaya; Stevo Julius; Toru Takebayashi; Yuji Sato; Hajime Uno; Masahiro Takeuchi; Kimiko Ishiguro; Marohito Murakami; Munekazu Ryuzaki; Hiroshi Itoh
Journal:  Hypertens Res       Date:  2008-10       Impact factor: 3.872

6.  Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressure.

Authors:  Emily B Levitan; Niko Kaciroti; Suzanne Oparil; Stevo Julius; Paul Muntner
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-10-09       Impact factor: 3.738

7.  Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial.

Authors:  Flávio D Fuchs; Sandra C Fuchs; Leila B Moreira; Miguel Gus; Antônio C Nóbrega; Carlos E Poli-de-Figueiredo; Décio Mion; Luiz Bortoloto; Fernanda Consolim-Colombo; Fernando Nobre; Eduardo Barbosa Coelho; José F Vilela-Martin; Heitor Moreno; Evandro José Cesarino; Roberto Franco; Andréa Araujo Brandão; Marcos R de Sousa; Antônio Luiz Pinho Ribeiro; Paulo Cesar Jardim; Abrahão Afiune Neto; Luiz César N Scala; Marco Mota; Hilton Chaves; João Guilherme Alves; Dario C Sobral Filho; Ricardo Pereira e Silva; José A Figueiredo Neto; Maria Cláudia Irigoyen; Iran Castro; André Avelino Steffens; Rosane Schlatter; Renato Bandeira de Mello; Francisca Mosele; Flávia Ghizzoni; Otávio Berwanger
Journal:  Trials       Date:  2011-03-05       Impact factor: 2.279
  7 in total
  1 in total

1.  Critique of re-analysis of the TROPHY study.

Authors:  Jay I Meltzer
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-06-26       Impact factor: 3.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.